Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT00071838
Show Display Options
Download search resultsDownload the search results for:
NCT00071838 (1 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Daclizumab

Indicates status has not been verified in more than two years